GE HealthCare Technologies has had a difficult year so far, with the stock down 23.7% year to date, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a discount. Recent headlines ranging from a prostate cancer research collaboration with Mayo Clinic to securities law investigations frame a valuation story that sits between long term potential in precision oncology and heightened risk perception.

• The share price has declined 23.7% year to date, which puts more focus on whether current levels already reflect the recent setbacks and ongoing uncertainty.
• On the upside, expanding capabilities in molecular imaging and precision oncology through the Mayo Clinic collaboration can support long term cash flow expectations. At the same time, the securities fraud investigations tied to recent earnings disclosures may weigh on sentiment and the multiple investors are willing to pay.
• The stock screens as cheap on Simply Wall St’s broader checks, with GE HealthCare Technologies flagged as undervalued in 6 of 6 valuation tests, and the DCF intrinsic value estimate indicating roughly 44% upside to the current price.

The issue now is whether that apparent discount in GE HealthCare Technologies is a genuine margin of safety or compensation for risks that could limit how much of the intrinsic value is realised.

Is GE HealthCare Technologies Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what GE HealthCare Technologies could be worth based on projected future cash flows. For the latest twelve months, the company generated about $1.6b in free cash flow, and the model assumes these cash flows continue growing rather than shrinking, using a 2 Stage Free Cash Flow to Equity approach.

On these assumptions, the DCF points to an intrinsic value of about $113 per share, which is above the current market price and implies the stock is trading at roughly a 44% discount. The securities fraud investigations following the Q1 2026 guidance cut may help explain why the price sits below this cash flow based estimate, as some investors may be assigning a higher risk premium.

On balance, the Discounted Cash Flow (DCF) workup suggests GE HealthCare Technologies stock currently appears undervalued based on these model assumptions.

Our Discounted Cash Flow (DCF) analysis suggests GE HealthCare Technologies is undervalued by 44.0%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Is GE HealthCare Technologies a Bargain on Earnings?

The P/E ratio is a useful way to look at GE HealthCare Technologies because earnings are a key focus for many investors in established medical equipment companies. GE HealthCare Technologies currently trades on a P/E of about 15.1x, which sits well below the Medical Equipment industry average of roughly 26.1x and the peer group around 25.3x.

Simply Wall St’s fair P/E ratio for GE HealthCare Technologies is estimated at about 26.9x, based on factors such as growth, margins, size and risk. That is materially higher than the current 15.1x, indicating a sizeable gap between what the model suggests could be a reasonable earnings multiple and what the market is currently paying.

On this P/E measure, GE HealthCare Technologies stock appears undervalued compared with both its industry and the fair ratio estimate.

The GE HealthCare Technologies Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for GE HealthCare Technologies connect the valuation puzzle above with clear scenarios for the future by spelling out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page. Each narrative ties a fair value to a specific combination of potential catalysts and risks so you can later compare which version of GE HealthCare Technologies' story is actually unfolding.

One of the top community narratives on GE HealthCare Technologies: 21% undervalued

"The pipeline of new high-impact products, like Radiopharmaceuticals, Total Body PET, and Photon Counting CT, is anticipated to drive future revenue growth and potentially improve margins..."

Do you think there's more to the story for GE HealthCare Technologies? Head over to our Community to see what others are saying!

The Bottom Line

For GE HealthCare Technologies, both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple view currently indicate that the stock screens as undervalued, with the broader checks also aligning on the same side. This alignment suggests that the key question is not whether the stock appears cheap, but why the discount exists and how long it might persist. The central issue for investors is whether concerns around the securities law investigations and execution on its precision oncology ambitions prove to be temporary sentiment issues or a lasting drag on how much of that intrinsic value is ultimately realised.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.